Jazz Pharmaceuticals PLC | Ownership
Companies that own Jazz Pharmaceuticals PLC
Fidelity Management & Research Co.
6,469,551
10.71%
667,923
0.11%
06/30/2018
Putnam Investment Management LLC
4,910,361
8.13%
-2,271,515
1.62%
06/30/2018
The Vanguard Group, Inc.
4,804,506
7.95%
58,556
0.03%
06/30/2018
BlackRock Fund Advisors
3,264,860
5.41%
1,198,399
0.03%
06/30/2018
TIAA-CREF Investment Management LLC
1,316,565
2.18%
75,113
0.11%
06/30/2018
JPMorgan Investment Management, Inc.
1,310,285
2.17%
192,210
0.07%
06/30/2018
Partner Fund Management LP
1,256,240
2.08%
105,175
3.72%
06/30/2018
SSgA Funds Management, Inc.
1,211,983
2%
528,933
0.02%
06/30/2018
Boston Partners Global Investors, Inc.
1,089,656
1.8%
18,821
0.2%
06/30/2018
OrbiMed Advisors LLC
1,040,100
1.72%
0
1.85%
06/30/2018
| Address |
Waterloo Exchange
Dublin Dublin 4
Ireland
|
|
Employees
|
- |
| Website |
http://www.jazzpharma.com |
| Updated |
07/08/2019 |
| Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. |
